|Awarded On||November 19, 2014|
|Title||Targeting the DC-HIL Receptor for Anti-Cancer Immunotherapy|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Kiyoshi Ariizumi|
|Cancer Sites||Bladder, Breast, Cervix Uteri, Colorectal, Kidney and Renal Pelvis, Lung and Bronchus, Melanoma, Pancreas, Prostate, Skin|
Despite new advances in cancer treatments, survival of patients with advanced or widespread cancer remains poor because many cancers can weaken the immune system by activating a special type of white blood cells called myeloid-derived suppressor cells (MDSC) that prevents natural killing of cancer cells.
We discovered that mice and patients with melanoma (but not healthy mice or individuals) express a protein (termed DC-HIL) on the surface of MDSC that is responsible for their ability to prevent natural killing of cancer cells. Taking away the DC-HIL gene or blocking its function (through a specific antibody) stops the activation and expansion of MDSC, reactivates the cancer-killing ability...